Aspen Pharma Group is a 170-year-old global specialty and branded multinational pharmaceutical company with a presence in over 50 countries, aiming to improve the health of patients in more than 150 countries. With approximately 9,100 employees, the company focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering hospital and consumer markets. Their key business segments include Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands. Aspen operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from stringent global regulatory agencies including the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines. The company's last investment of $30.00M was secured on 12 December 2022, with participation from notable investors such as the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations. With a strong presence in the healthcare, manufacturing, and pharmaceutical industries, Aspen Pharma Group stands as a significant player in the global pharmaceutical market, striving to provide high-quality, affordable medicines to patients worldwide.
